Clinical Trial: Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226557) titled 'Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation' on Nov. 05.

Brief Summary: This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.

Study Start Date: Jan. 01

Study Type: OBSERVATIONAL

Condition: Carbapenem Resistant Bacterial Infection Acinetobacter Baumannii Infection Antimicrobial Drug Resistance

Recruitment Status: ...